VJOncology is committed to improving our service to you

GU Cancers 2019 | Predicting PD-1 checkpoint inhibitor sensitivity in prostate cancer: potential molecular biomarkers

VJOncology is committed to improving our service to you

Emmanuel Antonarakis

Emmanuel Antonarakis, MBBCh, of Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA. Dr Antonarakis discusses a recent publication by his group on the need for a new molecular taxonomy to predict immune checkpoint inhibitor sensitivity in prostate cancer, highlighting three potential molecular biomarkers for PD-1 inhibitor response.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter